What does RCPHARM do?

RCPHARM is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 14 September 2010, 1 establishment.

What is the address of RCPHARM?

The registered office of RCPHARM is located at Blauwe Vogellaan 42, 1150 Sint-Pieters-Woluwe.

Is RCPHARM still active?

Yes. According to the CBE (15 November 2026) RCPHARM is active, legal situation “Normale toestand”, started on 14 September 2010.

Is RCPHARM registered on Peppol?

Yes, RCPHARM is registered on the Peppol network with ID 0208:0829235182.

What is the enterprise number of RCPHARM?

The enterprise number of RCPHARM is BE0829235182.

When was RCPHARM founded?

RCPHARM was founded on 14 September 2010.

Who are the directors of RCPHARM?

According to the 2025 annual accounts, the directors of RCPHARM are: Mohamed Rahmoun.

Is RCPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 September 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did RCPHARM make in 2025?

RCPHARM posted a profit after taxes of € 245,245 in financial year 2025.

What is the revenue of RCPHARM?

As a small company, RCPHARM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 56,704.

RCPHARM (Private Limited) - Sint-Pieters-Woluwe

Dossier RCPHARM, printed on 15 November 2026 from databakkes.be/en/0829235182/rcpharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

RCPHARM from Sint-Pieters-Woluwe, company number BE0829235182, closed financial year 2025 with a result of € 245,245 after tax. For that financial year RCPHARM recorded a gross margin of € 56,704 and equity of € 997,212. Compared with financial year 2024, the result moved from € 148,204 to € 245,245. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.

What it is worth Growing

€ 997,212

▲ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 245,245

▲ 65% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,832

▼ 41% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 841,058.

Debts at end 2025

Bank debt ≈ 3 years to go

€ 313,198

▼ 29% vs 2024

€ 89,767 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 214

▼ 92% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,617

▼ 12% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 73,245 Gross margin 2022: € 73,245 First fiscal year in the series	€ 57,949 Gross margin 2023: € 57,949 ▼ 21% vs 2022 (€ 73,245) Unfavourable step	€ 52,506 Gross margin 2024: € 52,506 ▼ 9% vs 2023 (€ 57,949) Unfavourable step	€ 56,704 Gross margin 2025: € 56,704 ▲ 8% vs 2024 (€ 52,506) Favourable step	▲ 8%
Profit after taxes	€ 45,630 Profit after taxes 2022: € 45,630 First fiscal year in the series	€ 36,392 Profit after taxes 2023: € 36,392 ▼ 20% vs 2022 (€ 45,630) Unfavourable step	€ 148,204 Profit after taxes 2024: € 148,204 ▲ € 111,813 vs 2023 (€ 36,392) Favourable step	€ 245,245 Profit after taxes 2025: € 245,245 ▲ 65% vs 2024 (€ 148,204) Favourable step	▲ 65%
Equity	€ 567,370 Equity 2022: € 567,370 First fiscal year in the series	€ 603,762 Equity 2023: € 603,762 ▲ 6% vs 2022 (€ 567,370) Favourable step	€ 751,967 Equity 2024: € 751,967 ▲ 25% vs 2023 (€ 603,762) Favourable step	€ 997,212 Equity 2025: € 997,212 ▲ 33% vs 2024 (€ 751,967) Favourable step	▲ 33%
Total debts	€ 1,617,446 Total debts 2022: € 1,617,446 First fiscal year in the series	€ 1,576,070 Total debts 2023: € 1,576,070 ▼ 3% vs 2022 (€ 1,617,446) Favourable step	€ 1,434,109 Total debts 2024: € 1,434,109 ▼ 9% vs 2023 (€ 1,576,070) Favourable step	€ 1,189,754 Total debts 2025: € 1,189,754 ▼ 17% vs 2024 (€ 1,434,109) Favourable step	▼ 17%
Cash	€ 8,322 Cash 2022: € 8,322 First fiscal year in the series	€ 8,565 Cash 2023: € 8,565 ▲ 3% vs 2022 (€ 8,322) Favourable step	€ 8,152 Cash 2024: € 8,152 ▼ 5% vs 2023 (€ 8,565) Unfavourable step	€ 4,832 Cash 2025: € 4,832 ▼ 41% vs 2024 (€ 8,152) Unfavourable step	▼ 41%
Retained profit	€ 411,217 Retained profit 2022: € 411,217 First fiscal year in the series	€ 447,609 Retained profit 2023: € 447,609 ▲ 9% vs 2022 (€ 411,217) Favourable step	€ 595,813 Retained profit 2024: € 595,813 ▲ 33% vs 2023 (€ 447,609) Favourable step	€ 841,058 Retained profit 2025: € 841,058 ▲ 41% vs 2024 (€ 595,813) Favourable step	▲ 41%
Bank debt	€ 746,637 Bank debt 2022: € 746,637 First fiscal year in the series	€ 588,940 Bank debt 2023: € 588,940 ▼ 21% vs 2022 (€ 746,637) Favourable step	€ 438,157 Bank debt 2024: € 438,157 ▼ 26% vs 2023 (€ 588,940) Favourable step	€ 313,198 Bank debt 2025: € 313,198 ▼ 29% vs 2024 (€ 438,157) Favourable step	▼ 29%
Balance sheet total	€ 2,184,816 Balance sheet total 2022: € 2,184,816 First fiscal year in the series	€ 2,179,832 Balance sheet total 2023: € 2,179,832 Unchanged (€ 2,184,816) Unchanged	€ 2,186,075 Balance sheet total 2024: € 2,186,075 Unchanged (€ 2,179,832) Unchanged	€ 2,186,966 Balance sheet total 2025: € 2,186,966 Unchanged (€ 2,186,075) Unchanged

By gross margin, RCPHARM ranks 22nd of 50 companies with main activity “Activiteiten van holdings” in Sint-Pieters-Woluwe that publish figures (fiscal year 2025).

Key figures of RCPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

Ask about RCPHARM the way you would ask their accountant.

Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.

Connect ChatGPT or Claude for free

ChatGPT
Claude

Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.

What happened to RCPHARM?

What happened at RCPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 29, 2026 New annual accounts for financial year 2025: profit of € 245,245 (▲ 65% vs 2024). filed late Source: NBB ↗
2024 Mohamed Rahmoun became a director. NBB
Sep 14, 2010 Start of the company according to the CBE. KBO
Sep 13, 2010 New establishment in Sint-Pieters-Woluwe. KBO

In short

From € 45,630 profit in 2022 to € 245,245 profit in 2025.

Paid € 51,459 in corporate taxes since 2022.

Best year ever: 2025, with € 245,245 profit.

Original PDFs at the National Bank ↗

Management

Mohamed Rahmoun

RCPHARM

CYNARA

Behind RCPHARM is Mohamed Rahmoun. Mohamed Rahmoun is also behind CYNARA.

Directors

According to the 2025 annual accounts

Mohamed Rahmoun

Director

Also active at: CYNARA

since 2024

Establishments

Establishment units

Physical locations of this company

Registered office

Blauwe Vogellaan 42

1150 Sint-Pieters-Woluwe

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Similar companies in Sint-Pieters-Woluwe

Same main activity (Activiteiten van holdings), 64 active companies in Sint-Pieters-Woluwe, largest first.

MITSUI AGRISCIENCE INTERNATIONAL

€ 36.1 million revenue · 2026

PAUTRIC INVEST

€ 2.7 million revenue · 2025

Intys Invest

€ 1.3 million revenue · 2026

MIK

€ 788,797 gross margin · 2025

DESOMER ERIC

€ 662,721 gross margin · 2025

« Bymc »

€ 632,152 gross margin · 2025

All companies with this activity → Largest companies in Sint-Pieters-Woluwe →

Details

Company number

0829.235.182

VAT number

BE 0829.235.182

Registered office

Blauwe Vogellaan 42, 1150 Sint-Pieters-Woluwe

Names & denominations

RCPHARM

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

14 September 2010

Peppol

Active · Active since 22 Dec 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

RCPHARM

Warning lights

Financials

Ask about RCPHARM the way you would ask their accountant.

What happened to RCPHARM?

Management

Directors

Establishments

Establishment units

Similar companies in Sint-Pieters-Woluwe

Details

Frequently asked questions